Literature DB >> 17599085

Utilizing RNA interference to enhance cancer drug discovery.

Elizabeth Iorns1, Christopher J Lord, Nicholas Turner, Alan Ashworth.   

Abstract

With the development of RNA interference (RNAi) libraries, systematic and cost-effective genome-wide loss-of-function screens can now be carried out with the aim of assessing the role of specific genes in neoplastic phenotypes, and the rapid identification of novel drug targets. Here, we discuss the existing applications of RNAi in cancer drug discovery and highlight areas in this process that may benefit from this technology in the future.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17599085     DOI： 10.1038/nrd2355

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  101 in total

1.  A genome-wide RNAi screen for polypeptides that alter rpS6 phosphorylation.

Authors:  Angela Papageorgiou; Joseph Avruch
Journal:  Methods Mol Biol       Date:  2012

2.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

Review 3.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

Review 4.  Preclinical development of molecular-targeted agents for cancer.

Authors:  Alberto Ocana; Atanasio Pandiella; Lillian L Siu; Ian F Tannock
Journal:  Nat Rev Clin Oncol       Date:  2010-12-07       Impact factor: 66.675

5.  Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.

Authors:  Elena V Sheveleva; Terry H Landowski; Betty K Samulitis; Geoffrey Bartholomeusz; Garth Powis; Robert T Dorr
Journal:  Mol Cancer Res       Date:  2012-01-24       Impact factor: 5.852

6.  Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM.

Authors:  Long Sheng; Maoming Xiong; Cong Li; Xiangling Meng
Journal:  Pathol Oncol Res       Date:  2013-12-11       Impact factor: 3.201

7.  Integrated chemical genomics reveals modifiers of survival in human embryonic stem cells.

Authors:  Robert Damoiseaux; Sean P Sherman; Jackelyn A Alva; Cory Peterson; April D Pyle
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

8.  Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers.

Authors:  Gregory R Hoffman; Rami Rahal; Frank Buxton; Kay Xiang; Gregory McAllister; Elizabeth Frias; Linda Bagdasarian; Janina Huber; Alicia Lindeman; Dongshu Chen; Rodrigo Romero; Nadire Ramadan; Tanushree Phadke; Kristy Haas; Mariela Jaskelioff; Boris G Wilson; Matthew J Meyer; Veronica Saenz-Vash; Huili Zhai; Vic E Myer; Jeffery A Porter; Nicholas Keen; Margaret E McLaughlin; Craig Mickanin; Charles W M Roberts; Frank Stegmeier; Zainab Jagani
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-11       Impact factor: 11.205

Review 9.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

Review 10.  Personalized Cancer Models for Target Discovery and Precision Medicine.

Authors:  Carla Grandori; Christopher J Kemp
Journal:  Trends Cancer       Date:  2018-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.